Cerebrolysin is not a single molecule but a standardized mixture of peptides and free amino acids produced by enzymatically breaking down purified pig brain protein. Manufactured by Ever Pharma of Austria and described as a neuropeptide preparation with neurotrophic action, it is prescribed for neurological conditions in dozens of countries yet holds no United States Food and Drug Administration approval. Its identity rests on a controlled manufacturing profile rather than one named active ingredient, and the strength of its clinical evidence remains debated.
Cerebrolysin is a porcine brain-derived mixture of low-molecular-weight peptides (below roughly 10 kilodaltons) and free amino acids, made by standardized enzymatic proteolysis and marketed by Ever Pharma of Austria, and it is not approved by the US Food and Drug Administration.
Cerebrolysin sits apart from most prescription drugs because it is a complex biological mixture, not one precisely characterized molecule. Its manufacturer classifies it as a neuropeptide preparation with neurotrophic and neuroprotective action, a description of composition and intended direction rather than proof of a defined receptor mechanism.
Cerebrolysin is classified by its manufacturer as a neuropeptide preparation, meaning its identity is defined by a standardized peptide and amino acid profile rather than by a single, fully characterized active molecule.
The starting material is brain tissue harvested from pigs, which makes Cerebrolysin a porcine-derived biological rather than a synthetic drug. Porcine brain is used because it is a rich, well-characterized source of the structural and signaling proteins found in mammalian nervous tissue, though an animal-tissue origin carries safety and sourcing questions a synthetic molecule never raises.
Cerebrolysin is manufactured from defatted porcine (pig) brain protein, an animal-tissue origin that introduces prion-safety and sourcing controls not required for synthetic peptides.
Cerebrolysin's composition splits into two fractions that differ sharply in size and in the role the manufacturer assigns them. Free amino acids make up the bulk of the nitrogen content, while the smaller peptide fraction is the part credited with the neurotrophic activity, and neither is isolated and named the way a single-molecule drug's active ingredient would be.
| Fraction | Free amino acids | Low-molecular-weight peptides |
|---|---|---|
| Share of content | Majority of total nitrogen | Smaller proportion |
| Molecular size | Individual amino acids | Below roughly 10 kDa |
| Assigned role | Bulk material, not the credited actor | Credited with neurotrophic and neuroprotective activity |
Cerebrolysin consists of a majority free-amino-acid fraction plus a smaller fraction of peptides below roughly 10 kilodaltons, with the peptide fraction credited by the manufacturer as the source of neurotrophic activity.
Turning pig brain into an injectable solution is a controlled digestion, not a simple extraction, and the whole process is built to reproduce the same peptide profile batch after batch. The manufacturer relies on tightly specified enzymatic conditions and release testing because a tissue extract is inherently harder to keep consistent than a synthesized molecule.
Cerebrolysin is produced by standardized enzymatic proteolysis of defatted porcine brain protein, followed by purification, contaminant-reduction steps, and per-batch release testing against a defined peptide-size specification.
Cerebrolysin's regulatory standing splits along a hard line: it is an authorized, decades-old prescription product across much of Europe and Asia, and an unapproved product in the United States. Ever Pharma of Austria, formerly EBEWE Neuro Pharma, holds marketing authorization in dozens of countries, but the molecule has never cleared the FDA's review for safety and efficacy, so it cannot be legally marketed or prescribed as a drug in the US.
Cerebrolysin holds marketing authorization in dozens of countries but has never received US FDA approval, so any supply reaching United States consumers moves through importation or gray-market channels outside regulatory oversight.
Cerebrolysin comes only as a sterile solution for injection, never as a pill, and that is a matter of chemistry rather than preference. Swallowed, its peptides would be broken down into constituent amino acids in the digestive tract before they could act, so parenteral delivery is essential to the product's rationale, and dosing runs as a course rather than a one-time treatment.
Cerebrolysin is supplied only as a sterile aqueous solution given by intravenous infusion or intramuscular injection, because oral dosing would let the digestive tract break its peptides down before they could act.
The manufacturer ties Cerebrolysin's proposed effects to its peptide fraction, which is said to mimic the body's own neurotrophic factors, the molecules that promote the survival, growth, and repair of nerve cells. A plausible biological story is not the same as demonstrated benefit, and separating the two matters most here: the composition supports a coherent hypothesis, while whether the product actually works across its indications is a separate question the current evidence does not settle.
Cerebrolysin's proposed neurotrophic action is a mechanistic hypothesis based on its peptide fraction rather than proven clinical benefit, and because it is a standardized mixture rather than isolated peptides, its clinical evidence across stroke, brain injury, and dementia remains mixed and debated.
Educational use only. This article describes what the published scientific and clinical literature reports about Cerebrolysin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
